

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

Silvia Piconese, Barbara Valzasina, and Mario P. Colombo

Vol. 205, No. 4, April 14, 2008. Pages 825–839.

The authors regret that two of the flow cytometry histograms in Fig. 3 C were inadvertently duplicated. The corrected figure and its legend appear below.




Figure 3. Tumor-infiltrating T reg cells express functional OX40. (A) TILs were purified from a pool of CT26 tumor nodules, and the CD4⁺ cell population was analyzed by flow cytometry (percentages are shown). As controls, CD4⁺ T cells were purified from the spleens of tumor-free mice (STF). (top) On gated CD4⁺ T cells, the expression of Foxp3 versus CD25 was evaluated. (bottom) Among CD4⁺ CD25⁺ T cells, Foxp3 versus OX40 expression is shown. (B) OX40 expression was evaluated on gated CD4⁺ Foxp3⁺ T cells from TILs of tumor-bearing mice. As controls, isotype staining on Foxp3⁺ TILs and OX40 staining on Foxp3⁺ CD4⁺ splenocytes from tumor-free mice are shown. (C) CD4⁺ CD25⁻ T cells (Teff), obtained from the spleens of tumor-free mice, were CFSE labeled and seeded either alone or combined at 1:1, 1:2, or 1:4 ratios with unlabeled CD4⁺ T cells purified from TILs (T reg TIL) of tumor-bearing mice, either untreated or 6 h after intratumor OX86 injection (anti-OX40 in vivo). No major differences in the composition of tumor-infiltrating CD4⁺ T cells or in Foxp3 expression were evident 6 h after treatment. As controls, CD4⁺ CD25⁻ T cells from spleens of tumor-free mice were used (T reg STF). T reg cells were either pretreated with anti-OX40 mAb in vitro or with rat IgG as mock control. After 72 h, effector T cells were tested for CFSE dilution as a marker of proliferation. Representative plots of one out of three independent experiments are shown and indicate percentages of proliferating (CFSE^{low}) versus resting (CFSE^{high}) effector T cells.